[A18-42] Benralizumab (asthma) - Addendum to Commission A18-11
Last updated 02.08.2018
Project no.:
A18-42
Commission:
Commission awarded on 26.06.2018 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Airways and respiratory system
Add-on maintenance treatment in adults with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting beta agonists
Conclusion of dossier assessment A18-11 unchanged
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A18-11 | Benralizumab (asthma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-08-02 A G-BA decision was published.